◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Emcure Pharmaceuticals Limited (EMCURE)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-11-02
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine.
关键数据
- 市值: ₹357 billion
- 收入（截至 2026-03-31 财年）: ₹91.2B
- 净利润: ₹9.2B
- 毛利率: 57.2%
- 净利率: 10.1%
查看交互式图表与完整报表 →
估值模型 (DCF) →
年度利润表
| 利润表 | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|
| 总收入 | ₹96.8B | ₹91.2B | ₹78.1B | ₹65.8B | ₹59.3B | — |
| 毛利 | ₹57.6B | ₹52.2B | ₹44.9B | ₹39.7B | ₹35.2B | — |
| 营业利润（EBIT） | ₹14.7B | ₹13.7B | ₹10.8B | ₹9.2B | ₹9.4B | — |
| 净利 | ₹10.1B | ₹9.2B | ₹6.8B | ₹5.0B | ₹5.3B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 EMCURE 交互式查看器。 /companies/us/EMCURE
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.